¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"renal threshold for glucose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • renal artery embolism
    ½Åµ¿¸Æ»öÀü¼ú
  • renal artery stenosis
    ½Åµ¿¸ÆÇùÂø
  • renal artery,occlusion of
    ¡­ÀÇ Æó¼â(øÍáð)
  • renal artery,stenosis
    ½Åµ¿¸Æ ÇùÂø(ãìÔÑØæ úòó·)
  • renal asthma
    ½Å¼ºÃµ½Ä(ãìàõô·ãÓ).
  • renal asthma
    ½Å¼ºÃµ½Ä(¡­ô·ãÓ)
  • renal atheroembolic disease
    ½ÅÁ×»óÀü»öº´(ãìñÔßÚîûßáÜ»),½ÅÁ×Á¾»öÀüº´(ãìñÔðþßÝîûÜ»)
  • renal atrophy
    ½ÅÀ§Ãà(ãìê×õê).
  • renal atrophy
    ½ÅÀ§Ãà(ãìê×õê)
  • renal atrophy
    ½ÅÀ§Ãà
  • renal autonomic plexus
    ½Å ÀÚÀ²½Å°æÃÑ
  • renal autotransplantation
    ½Å ÀÚ°¡À̽Ä
  • renal azotemia
    ½Å¼º °íÁú¼ÒÇ÷Áõ
  • renal ballottement
    ½ÅºÎ±¸°¨(ãìݩϹÊï).
  • renal ballottement
    ½ÅºÎ±¸°¨(ãìݩϹÊï)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • threshold odor number
    ¹®ÅÎÈİ¢Áö¼ö, ¿ªÄ¡Èİ¢Áö¼ö.
  • threshold of audibility
    °¡Ã»¿ªÄ¡
  • threshold of audibility
    °¡Ã»¿ªÄ¡(ʦôéÚ¿ö·).
  • threshold of discomfort
    ºÒÄ迪ġ.
  • threshold of feeling
    °¨°¢¹®ÅÎ, °¨°¢ÇѰè(ÊïÊÆùÚÍ£).
  • threshold of hearing
    ÃÖ¼Ò°¡Ã»¿ªÄ¡
  • threshold of hearing
    ÃÖ¼Ò°¡Ã»¿ªÄ¡(õÌá³Ê¦ôéæ´ö·).
  • threshold potential
    ¿ªÄ¡ÀüÀ§
  • threshold potential
    ¿ªÄ¡ÀüÀ§.
  • threshold stimulus
    ¹®ÅÎÀÚ±Ø, ¿ªÄ¡ÀÚ±Ø(Ú¿ö·ô§Ð½)
  • threshold stimulus
    ¹®ÅÎÀÚ±Ø, ¿ªÄ¡ÀÚ±Ø(Ú¿ö·ô§Ð½).
  • threshold substance
    À¯¿ªÄ¡¹°Áú(êóÚ¿ö· Úªòõ).
  • threshold tone decay test
    ¿ªÄ¡Ã»°¢ÇÇ·Î °Ë»ç
  • threshold value
    ¿ªÄ¡°¡
  • threshold value
    ¹®Åΰª, ¿ªÄ¡(Ú¿ö·).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
PPT parietal pleural tissue; partial prothrombin time; peak-to-peak threshold; Pfeiffer-Palm-Teller [syn...
PT pain threshold; parathormone; parathyroid; paroxysmal tachycardia; part time; patient; pericardial t...
PTAT pure tone average threshold
RDT retinal damage threshold; routine dialysis therapy
SDT sensory detection theory; right sacrotransverse [fetal position] [Lat. sacrodextra transversa]; sign...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
STR scotopic threshold response
T threshold
TS threshold shift
ARI 5--acute renal insufficiency
ARCD Acquired renal cystic disease
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • renal sinus
    ½Åµ¿
  • renal solute load
    ½Å ¿ëÁú ºÎÇÏ
  • renal storm
    ½Å¼º ±Þ¹ß Áõ»ó
  • renal surgery
    ½ÅÀå ¼ö¼ú
  • renal teratoma
    ½Å ±âÇüÁ¾
  • renal thyroidization
    ½ÅÀÇ °©»ó¼±È­
  • renal transplantation
    ½Å À̽Ä
  • renal tuberculosis
    ½Å °áÇÙ
  • renal tubular secretion
    ½Å ¼¼´¢°ü ºÐºñ
  • renal tuburlar acidosis
    ½Å ¼¼´¢°ü »êÁõ
  • renal tumor
    ½Å Á¾¾ç
  • renal uremia
    ½Å¼º ¿äµ¶Áõ
  • renal vascular injury
    ½Å Ç÷°ü ¼Õ»ó
  • renal vein
    ½Å Á¤¸Æ
  • renal vein thrombosis
    ½Å Á¤¸Æ Ç÷ÀüÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
fasting blood glucose <endocrinology, investigation> A method for finding out how much glucose (sugar) is in the blood. The test can show if a person has diabetes.
A blood sample is taken in a lab or doctor's office. The test is usually done in the morning before the person has eaten. The normal, nondiabetic range for blood glucose is from 70 to 110 mg/dl, depending on the type of blood being tested. If the level is over 140 mg/dl, it usually means the person has diabetes (except for newborns and some pregnant women).
(09 Oct 1997)
fasting glucose <endocrinology, investigation> A measurement of the blood glucose in the morning prior to the ingestion of any food for the prior 12 hours.
(27 Sep 1997)
UPD-glucose-thiohydroximate glucosyltransferase <enzyme> From brassica; catalyses the glucosylation of phenylacetothiohydroximate in the presence of udp-glucose to form desulfobenzylglucosinolate
Registry number: EC 2.4.1.-
Synonym: udp-glc-th-glucosyltransferase
(26 Jun 1999)
uridine diphosphate glucose <chemical> A key intermediate in carbohydrate metabolism. Serves as a precursor of glycogen, can be metabolised into udpgalactose and udpglucuronic acid which can then be incorporated into polysaccharides as galactose and glucuronic acid. Also serves as a precursor of sucrose lipopolysaccharides, and glycosphingolipids.
Chemical name: Uridine 5'-(trihydrogen diphosphate), P'-alpha-D-glucopyranosyl ester
(12 Dec 1998)
uridine diphosphate glucose dehydrogenase <enzyme> An enzyme that catalyses the oxidation of udpglucose to udpglucuronate in the presence of NAD+.
Chemical name: UDPglucose:NAD+ 6-oxidoreductase
Registry number: EC 1.1.1.22
(12 Dec 1998)
utp-glucose-1-phosphate uridylyltransferase <enzyme> An enzyme that catalyses the formation of udpglucose from utp plus glucose 1-phosphate.
Chemical name: UTP:alpha-D-glucose-1-phosphate uridylyltransferase
Registry number: EC 2.7.7.9
(12 Dec 1998)
4-coumaroyl-D-glucose hydroxylase <enzyme> From sweet potato roots (ipomoea batatas); catalyses the conversion of p-coumaroyl-d-glucose to caffeoyl-d-glucose for chlorogenic acid biosynthesis in the presence of ascorbic acid; mw 33 kD; has weak polyphenol oxidase activity; also hydroxylates p-coumaric acid
Registry number: EC 1.14.17.-
Synonym: p-coumaroyl-d-glucose hydroxylase, cdg hydroxylase
(26 Jun 1999)
liquid glucose A pharmaceutic aid consisting of dextrose, dextrins, maltose, and water, obtained by the incomplete hydrolysis of starch.
(05 Mar 2000)
acute renal failure <nephrology> A sudden decline in renal function may be triggered by a number of acute disease processes.
Examples include sepsis (infection), shock, trauma, kidney stones, kidney infection, drug toxicity (aspirin or lithium), poisons or toxins (drug abuse) or after injection with an iodinated contrast dye (adverse effect).
Chronic renal failure represents a slow decline in kidney function over time. Chronic renal failure may be caused by a number of disorders which include long-standing hypertension, diabetes, congestive heart failure, lupus or sickle cell anaemia. Both forms of renal failure result in a life-threatening metabolic derangement.
(27 Sep 1997)
aminoaciduria, renal Impairment of renal tubular transport of amino acids.
(12 Dec 1998)
back-pressure renal atrophy <radiology> Caliectasis without obstruction, due to repeated episodes of obstruction, gradual loss of renal pyramids
(12 Dec 1998)
base of renal pyramid The outer broad part of a renal pyramid that lies next to the cortex.
Synonym: basis pyramidis renis.
(05 Mar 2000)
branchio-oto-renal syndrome <syndrome> An autosomal dominant disorder manifested by various combinations of preauricular pits, branchial fistulae or cysts, lacrimal duct stenosis, hearing loss, structural defects of the outer, middle, or inner ear, and renal dysplasia. Associated defects include asthenic habitus, long narrow facies, constricted palate, deep overbite, and myopia. Hearing loss may be due to mondini type cochlear defect and stapes fixation.
(12 Dec 1998)
capsular branches of renal artery <anatomy, artery> Branches arising from the renal artery outside of the kidney that are distributed to the renal capsule.
Synonym: rami capsulares arteriae renalis.
(05 Mar 2000)
captopril renal scan <radiology> In a kidney with a lesion in the afferent arteriole (e.g. Atherosclerotic plaque), reflex constriction of the efferent arteriole occurs through angiotensin system thus maintaining renal perfusion. ACE inhibition prevents constriction of efferent arteriole. Therefore, perfusion is decreased to a kidney with afferent lesions and the renal scan to looks WORSE. Bottom line: renal scans appear WORSE with captopril administration if there is a lesion in the afferent arteriole. See: renal artery stenosis
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á